| CAS NO: | 205923-56-4 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
Molecular Formula: C6484H10042N1732O2023S36
Molecular Weight: 145781.92
Synonym: Cetuximab (anti-EGFR); IMC 225; Hsdb 7454;CETUXIMAB; EGFR antibody; Unii-pqx0D8J21j;CETUXIMAB USP/EP/BP; CetuxiMab(C225); Immunoglobulin G1, anti-(human epidermal growth factor receptor) (human-mouse monoclon
| In vitro | Cetuximab (C225) is a monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for soluble EGFR by SPR. Cetuximab also exhibits a Kd of 0.147 nM for EGFR in fixed A431 cells by ELISA. Cetuximab (C225; 30 nM) time-dependently inhibits the proliferation of SCC-1, SCC-11B, SCC-38, and SCC-13Y cells after treatment for 8 d. Cetuximab (30 nM) causes G0/G1 arrest, induces apoptosis, and reduces Rb, p27KIP1, Bcl-2, and Bax expression in SCC-13Y cells. Cetuximab (30 nM) also enhances radiosensitivity and increases radiation-induced apoptosis in SCC-13Y cells. |
|---|---|
| In Vivo | Cetuximab (1 mg/injection) has effect on the tumour volume but the effect is more pronounced on UT-SCC-14 xenografts. In UT-SCC-14 xenografts, Cetuximab treatment significantly reduces the expression of EGFR, pEGFR and Ki67. The MCT1 and GLUT1 expression is significantly decreased in the Cetuximab-treated groups of both cell lines but differences are more pronounced in UT-SCC-14 xenografts. |
| Protocol | Cetuximab (C225) is a monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity |
| References | Clin Cancer Res. 1995 Nov;1(11):1311-8.; Cancer Res. 1999 Apr 15;59(8):1935-40. |
m.cnreagent.com